R-3692 Rociletinib, Free Base, >99%

Synonyms : [AVL-301] [CNX-419] [CO-1686]

  • Size
  • US $
  • £
  • ¥
  • 25 mg
  • 57
  • 46
  • 40
  • 6,100
  • Add to Cart Qty:
  • In stock
  • 50 mg
  • 79
  • 63
  • 56
  • 8,400
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 127
  • 102
  • 90
  • 13,500
  • Add to Cart Qty:
  • In stock
  • 200 mg
  • 211
  • 170
  • 150
  • 22,400
  • Add to Cart
  • Out of stock
  • 500 mg
  • 392
  • 317
  • 279
  • 41,700
  • Add to Cart
  • Out of stock
  • 1 g
  • 678
  • 549
  • 483
  • 72,100
  • Add to Cart
  • Out of stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 33 Other Countries
  • M.W. 555.55
  • C27H28F3N7O3
  • [1374640-70-6]

Certificate of Analysis

  • Rociletinib, also known as CO-1686, is an irreversible tyrosine kinase inhibitor with a Ki of 21.5 nM for the EGFR L858R/T790M mutant and a Ki of 303.3 nM for wt EGFR. It inhibited the growth of non-small cell lung cancer (NSCLC) cells expressing mutant EGFR, and it induced apoptosis. It also demonstrated in vivo anti-tumor activity in mice bearing NSCLC tumors with activating EGFR mutations. Walter A.O., et al. "Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC." Cancer Discov. 3: 1404-1415 (2013).
  • The T790M mutation is the most common reason for acquired resistance to existing EGFR inhibitors in NSCLC. Rociletinib potently inhibited mutant EGFR L858R/T790M with an IC50 < 0.51nM. Rociletinib blocked the growth of T790M-positive NSCLC cells in vitro and in vivo. Walter A.O., et al. "CO-1686, a novel mutant-selective EGFR inhibitor, overcomes T790M mediated resistance in non-small cell lung cancer (NSCLC)." http://www.clovisoncology.com/assets/pdf/CO-1686/Clovis-Avila_AACR_2012_CO-1686_Poster_ClovisFINAL_27MAR12.pdf
  • A phase I clinical trial in patients with EGFR mutated NSCLC demonstrated that rociletinib was well tolerated, and activity was observed in dose escalation cohorts. Sequist L.V., et al. "First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M." http://www.clovisoncology.com/files/CLVS_ASCO_2013_poster_CO1686_P1monotx_abstract2524.pdf
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.